. 2025 Apr 9;19(4):e0012993. doi: 10.1371/journal.pntd.0012993

Table 5. Logistic models to high^* neutralizing antibody titer for yellow fever 30–45 days after vaccination in adults (between 18 and 50 years) (n = 1,504).

Variables	Crude OR (95% CI)	Adjusted OR^** (95% CI)
IgG dengue pre-vaccination
Positive	0.45 (0.23–0.79)	0.41 (0.21–0.75)
Negative	1	1
IgG Zika pre-vaccination
Positive	0.92 (0.66–1.28)	1.12 (0.79–1.56)
Negative	1	1
Age (year)	1.02 (1.00–1.04)	1.02 (1.00–1.04)

Pre-vaccine yellow fever seropositive individuals and individuals who had seronegative and indeterminate titers 30–45 days post-vaccination were excluded.

Reference category: μFRNT YF ≤951 (low).

^**

Model adjusted by IgG dengue pre-vaccination, IgG Zika pre-vaccination, Age (years) and sex: AIC = 1,108.

Table 5. Logistic models to high* neutralizing antibody titer for yellow fever 30–45 days after vaccination in adults (between 18 and 50 years) (n = 1,504).

Table 5. Logistic models to high^* neutralizing antibody titer for yellow fever 30–45 days after vaccination in adults (between 18 and 50 years) (n = 1,504).